South Korea Central Bank Set to Raise Interest Rates as Inflation Stays Elevated 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Deutsche Bank Sees Global Capital Shifts Reshaping Long-Term U.S. Dollar Outlook 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Trump Administration Hands Over Key Evidence in Minnesota Immigration Shooting Investigations 
Dollar Eases as Middle East Conflict, Fed Outlook and Japan Pension Policy Drive FX Markets 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
In a rebuke to Trump, the Supreme Court rules that birthright citizenship is the law of the land 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Asia Stocks Slip as Iran-Hormuz Tensions Lift Oil Prices, Dollar and Bond Yields 
US Inflation Expected to Ease in June, but Fed Rate Hike Risks Persist Amid Middle East Tensions 
Gordie Howe Bridge to Open July 27 After U.S.-Canada Reach Toll Revenue Agreement 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
